GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaResearch Co Ltd (XKRX:214450) » Definitions » EV-to-EBITDA

PharmaResearch Co (XKRX:214450) EV-to-EBITDA : 9.48 (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is PharmaResearch Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmaResearch Co's enterprise value is ₩1,259,475 Mil. PharmaResearch Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩132,916 Mil. Therefore, PharmaResearch Co's EV-to-EBITDA for today is 9.48.

The historical rank and industry rank for PharmaResearch Co's EV-to-EBITDA or its related term are showing as below:

XKRX:214450' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.64   Med: 14.05   Max: 52.68
Current: 9.48

During the past 10 years, the highest EV-to-EBITDA of PharmaResearch Co was 52.68. The lowest was 6.64. And the median was 14.05.

XKRX:214450's EV-to-EBITDA is ranked worse than
53.51% of 456 companies
in the Biotechnology industry
Industry Median: 10.52 vs XKRX:214450: 9.48

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), PharmaResearch Co's stock price is ₩135900.00. PharmaResearch Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩7404.490. Therefore, PharmaResearch Co's PE Ratio for today is 18.35.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


PharmaResearch Co EV-to-EBITDA Historical Data

The historical data trend for PharmaResearch Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaResearch Co EV-to-EBITDA Chart

PharmaResearch Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.47 10.36 11.18 8.86 8.81

PharmaResearch Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.02 16.11 12.23 8.81 7.97

Competitive Comparison of PharmaResearch Co's EV-to-EBITDA

For the Biotechnology subindustry, PharmaResearch Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaResearch Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaResearch Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmaResearch Co's EV-to-EBITDA falls into.



PharmaResearch Co EV-to-EBITDA Calculation

PharmaResearch Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1259475.199/132915.776
=9.48

PharmaResearch Co's current Enterprise Value is ₩1,259,475 Mil.
PharmaResearch Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩132,916 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaResearch Co  (XKRX:214450) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PharmaResearch Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=135900.00/7404.490
=18.35

PharmaResearch Co's share price for today is ₩135900.00.
PharmaResearch Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩7404.490.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


PharmaResearch Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmaResearch Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaResearch Co (XKRX:214450) Business Description

Traded in Other Exchanges
N/A
Address
74 Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Seongnam, KOR, 463-400
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.

PharmaResearch Co (XKRX:214450) Headlines

No Headlines